CA2879249A1 - 3,4-disubstituted oxazolidinone derivatives and their use as inhibitors of the calcium activated potassium channel - Google Patents
3,4-disubstituted oxazolidinone derivatives and their use as inhibitors of the calcium activated potassium channel Download PDFInfo
- Publication number
- CA2879249A1 CA2879249A1 CA2879249A CA2879249A CA2879249A1 CA 2879249 A1 CA2879249 A1 CA 2879249A1 CA 2879249 A CA2879249 A CA 2879249A CA 2879249 A CA2879249 A CA 2879249A CA 2879249 A1 CA2879249 A1 CA 2879249A1
- Authority
- CA
- Canada
- Prior art keywords
- phenyl
- compound according
- fluoro
- alkyl
- bis
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Abandoned
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
- C07D413/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings
- C07D413/04—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings directly linked by a ring-member-to-ring-member bond
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
- A61P11/06—Antiasthmatics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P13/00—Drugs for disorders of the urinary system
- A61P13/12—Drugs for disorders of the urinary system of the kidneys
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
- A61P35/02—Antineoplastic agents specific for leukemia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
- A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P7/00—Drugs for disorders of the blood or the extracellular fluid
- A61P7/10—Antioedematous agents; Diuretics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D263/00—Heterocyclic compounds containing 1,3-oxazole or hydrogenated 1,3-oxazole rings
- C07D263/02—Heterocyclic compounds containing 1,3-oxazole or hydrogenated 1,3-oxazole rings not condensed with other rings
- C07D263/08—Heterocyclic compounds containing 1,3-oxazole or hydrogenated 1,3-oxazole rings not condensed with other rings having one double bond between ring members or between a ring member and a non-ring member
- C07D263/16—Heterocyclic compounds containing 1,3-oxazole or hydrogenated 1,3-oxazole rings not condensed with other rings having one double bond between ring members or between a ring member and a non-ring member with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
- C07D263/18—Oxygen atoms
- C07D263/20—Oxygen atoms attached in position 2
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D263/00—Heterocyclic compounds containing 1,3-oxazole or hydrogenated 1,3-oxazole rings
- C07D263/02—Heterocyclic compounds containing 1,3-oxazole or hydrogenated 1,3-oxazole rings not condensed with other rings
- C07D263/30—Heterocyclic compounds containing 1,3-oxazole or hydrogenated 1,3-oxazole rings not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members
- C07D263/32—Heterocyclic compounds containing 1,3-oxazole or hydrogenated 1,3-oxazole rings not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members with only hydrogen atoms, hydrocarbon or substituted hydrocarbon radicals, directly attached to ring carbon atoms
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
- C07D413/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings
- C07D413/06—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings linked by a carbon chain containing only aliphatic carbon atoms
Landscapes
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Health & Medical Sciences (AREA)
- Veterinary Medicine (AREA)
- Pharmacology & Pharmacy (AREA)
- Public Health (AREA)
- General Health & Medical Sciences (AREA)
- Medicinal Chemistry (AREA)
- Animal Behavior & Ethology (AREA)
- Life Sciences & Earth Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Engineering & Computer Science (AREA)
- Immunology (AREA)
- Urology & Nephrology (AREA)
- Rheumatology (AREA)
- Pulmonology (AREA)
- Hematology (AREA)
- Neurosurgery (AREA)
- Cardiology (AREA)
- Oncology (AREA)
- Neurology (AREA)
- Transplantation (AREA)
- Orthopedic Medicine & Surgery (AREA)
- Physical Education & Sports Medicine (AREA)
- Diabetes (AREA)
- Vascular Medicine (AREA)
- Pain & Pain Management (AREA)
- Heart & Thoracic Surgery (AREA)
- Biomedical Technology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Heterocyclic Carbon Compounds Containing A Hetero Ring Having Nitrogen And Oxygen As The Only Ring Hetero Atoms (AREA)
- Plural Heterocyclic Compounds (AREA)
- Epidemiology (AREA)
- Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| EP12190319 | 2012-10-29 | ||
| EP12190319.9 | 2012-10-29 | ||
| PCT/EP2013/072361 WO2014067861A1 (en) | 2012-10-29 | 2013-10-25 | 3,4-disubstituted oxazolidinone derivatives and their use as inhibitors of the calcium activated potassium channel |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| CA2879249A1 true CA2879249A1 (en) | 2014-05-08 |
Family
ID=47143594
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CA2879249A Abandoned CA2879249A1 (en) | 2012-10-29 | 2013-10-25 | 3,4-disubstituted oxazolidinone derivatives and their use as inhibitors of the calcium activated potassium channel |
Country Status (23)
| Country | Link |
|---|---|
| US (1) | US9611232B2 (https=) |
| EP (1) | EP2912034B1 (https=) |
| JP (1) | JP6216385B2 (https=) |
| KR (1) | KR20150075091A (https=) |
| CN (1) | CN104781256B (https=) |
| AR (1) | AR093168A1 (https=) |
| AU (1) | AU2013339607A1 (https=) |
| BR (1) | BR112015003996A2 (https=) |
| CA (1) | CA2879249A1 (https=) |
| CL (1) | CL2015000906A1 (https=) |
| CO (1) | CO7170170A2 (https=) |
| CR (1) | CR20150159A (https=) |
| EA (1) | EA026161B1 (https=) |
| IL (1) | IL237331A0 (https=) |
| IN (1) | IN2015DN00961A (https=) |
| MA (1) | MA38135B1 (https=) |
| MX (1) | MX2015002399A (https=) |
| PE (1) | PE20150775A1 (https=) |
| PH (1) | PH12015500292A1 (https=) |
| SG (1) | SG11201500585XA (https=) |
| TW (1) | TW201422596A (https=) |
| UA (1) | UA114649C2 (https=) |
| WO (1) | WO2014067861A1 (https=) |
Families Citing this family (3)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| KR102047502B1 (ko) * | 2016-06-20 | 2019-11-22 | 셀라이온바이오메드 주식회사 | 포타슘 채널 단백질을 이용한 암 진단용 조성물 |
| EA202192544A1 (ru) | 2019-03-22 | 2022-03-22 | Саниона А/С | Новые ингибиторы калиевых каналов |
| CA3193349A1 (en) * | 2020-09-22 | 2022-03-31 | Saniona A/S | Novel potassium channel inhibitors |
Family Cites Families (16)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| DE2538424C2 (de) * | 1975-08-29 | 1983-01-05 | Nordmark-Werke Gmbh, 2000 Hamburg | 4-substituierte 5-Phenyl-oxazolidon-(2)- Verbindungen und ein diese enthaltendes pharmazeutisches Präparat |
| DE3687870T2 (de) * | 1985-09-09 | 1993-08-19 | Otsuka Pharma Co Ltd | 2-oxa-isocephemverbindungen, sie enthaltende zusammensetzungen und verfahren zu deren herstellung. |
| KR930703262A (ko) * | 1990-11-06 | 1993-11-29 | 스튜어트 알. 슈터 | 이미다졸리디논 화합물 |
| DE4439846A1 (de) * | 1994-11-08 | 1996-05-09 | Merck Patent Gmbh | Adhäsionsrezeptor-Antagonisten |
| WO1997031892A1 (fr) * | 1996-03-01 | 1997-09-04 | Sankyo Company, Limited | Derives d'acide hydroxamique |
| CA2349616A1 (en) * | 1998-12-04 | 2000-06-15 | Neurosearch A/S | New benzimidazolone-, benzoxazolone-, or benzothiazolone derivatives as ion channel modulating agents |
| JP3966693B2 (ja) * | 2000-01-20 | 2007-08-29 | エーザイ・アール・アンド・ディー・マネジメント株式会社 | 含窒素環化合物およびそれらを含んでなる医薬組成物 |
| US6906072B1 (en) * | 2000-01-20 | 2005-06-14 | Eisai Co., Ltd. | Piperazine compound and pharmaceutical composition containing the compound |
| ES2231581T3 (es) * | 2000-11-22 | 2005-05-16 | Bayer Healthcare Ag | Nuevos derivados de pirazolopiridina sustituidos con lactama. |
| CN1993347A (zh) | 2004-07-29 | 2007-07-04 | 默克公司 | 钾通道抑制剂 |
| DE102004060229A1 (de) * | 2004-12-15 | 2006-06-29 | Sanofi-Aventis Deutschland Gmbh | Neue zyklische Harnstoffe als Inhibitoren von Metallproteasen |
| US7378530B2 (en) * | 2005-02-22 | 2008-05-27 | Nereus Pharmaceuticals, Inc. | Anti-cancer and anti-microbial 5-membered heterocyclic compounds |
| US20100056637A1 (en) | 2005-12-20 | 2010-03-04 | Icagen, Inc. | Treatment methods using triaryl methane compounds |
| WO2007109098A2 (en) * | 2006-03-16 | 2007-09-27 | Azevan Pharmaceuticals, Inc. | HYDROXY AND KETO-SUBSTITUTED β-LACTAMYL ALKANEDIOIC ACIDS |
| TW201026708A (en) | 2008-12-12 | 2010-07-16 | Solvay Pharm Bv | Spiro azepane-oxazolidinones as Kv1.3 potassium channel blockers |
| WO2010123997A1 (en) * | 2009-04-22 | 2010-10-28 | Achaogen, Inc. | Carbacephem beta-lactam antibiotics |
-
2013
- 2013-10-25 CN CN201380056503.4A patent/CN104781256B/zh not_active Expired - Fee Related
- 2013-10-25 JP JP2015538458A patent/JP6216385B2/ja not_active Expired - Fee Related
- 2013-10-25 KR KR1020157011024A patent/KR20150075091A/ko not_active Withdrawn
- 2013-10-25 EP EP13783333.1A patent/EP2912034B1/en not_active Not-in-force
- 2013-10-25 UA UAA201504977A patent/UA114649C2/uk unknown
- 2013-10-25 IN IN961DEN2015 patent/IN2015DN00961A/en unknown
- 2013-10-25 CA CA2879249A patent/CA2879249A1/en not_active Abandoned
- 2013-10-25 MX MX2015002399A patent/MX2015002399A/es unknown
- 2013-10-25 MA MA38135A patent/MA38135B1/fr unknown
- 2013-10-25 PE PE2015000296A patent/PE20150775A1/es not_active Application Discontinuation
- 2013-10-25 WO PCT/EP2013/072361 patent/WO2014067861A1/en not_active Ceased
- 2013-10-25 EA EA201590729A patent/EA026161B1/ru not_active IP Right Cessation
- 2013-10-25 BR BR112015003996A patent/BR112015003996A2/pt not_active IP Right Cessation
- 2013-10-25 AU AU2013339607A patent/AU2013339607A1/en not_active Abandoned
- 2013-10-25 SG SG11201500585XA patent/SG11201500585XA/en unknown
- 2013-10-28 TW TW102138950A patent/TW201422596A/zh unknown
- 2013-10-28 AR ARP130103922A patent/AR093168A1/es unknown
-
2015
- 2015-01-16 CO CO15008510A patent/CO7170170A2/es unknown
- 2015-02-10 PH PH12015500292A patent/PH12015500292A1/en unknown
- 2015-02-19 IL IL237331A patent/IL237331A0/en unknown
- 2015-03-20 CR CR20150159A patent/CR20150159A/es unknown
- 2015-04-10 CL CL2015000906A patent/CL2015000906A1/es unknown
- 2015-04-29 US US14/699,144 patent/US9611232B2/en not_active Expired - Fee Related
Also Published As
| Publication number | Publication date |
|---|---|
| AU2013339607A1 (en) | 2015-02-05 |
| CO7170170A2 (es) | 2015-01-28 |
| JP2015535231A (ja) | 2015-12-10 |
| PE20150775A1 (es) | 2015-05-21 |
| MA38135B1 (fr) | 2018-11-30 |
| SG11201500585XA (en) | 2015-04-29 |
| EP2912034A1 (en) | 2015-09-02 |
| TW201422596A (zh) | 2014-06-16 |
| BR112015003996A2 (pt) | 2017-07-04 |
| US20150246894A1 (en) | 2015-09-03 |
| EA201590729A1 (ru) | 2015-07-30 |
| KR20150075091A (ko) | 2015-07-02 |
| EP2912034B1 (en) | 2017-05-31 |
| IN2015DN00961A (https=) | 2015-06-12 |
| HK1207632A1 (en) | 2016-02-05 |
| CL2015000906A1 (es) | 2015-09-11 |
| UA114649C2 (uk) | 2017-07-10 |
| EA026161B1 (ru) | 2017-03-31 |
| JP6216385B2 (ja) | 2017-10-18 |
| IL237331A0 (en) | 2015-04-30 |
| AR093168A1 (es) | 2015-05-20 |
| MA38135A2 (fr) | 2016-11-30 |
| US9611232B2 (en) | 2017-04-04 |
| WO2014067861A1 (en) | 2014-05-08 |
| CN104781256A (zh) | 2015-07-15 |
| MX2015002399A (es) | 2015-06-10 |
| PH12015500292A1 (en) | 2015-04-20 |
| CN104781256B (zh) | 2017-09-29 |
| CR20150159A (es) | 2015-04-30 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| US6977267B2 (en) | Spiro-hydantoin compounds useful as anti-inflammatory agents | |
| RU2645673C2 (ru) | Производные 2,5-диоксоимидазолидин-1-ил-3-фенилмочевины в качестве модуляторов формилпептидного рецептора 1 (fprl-1) | |
| US20110230493A1 (en) | 1-OXA-8-Azaspiro [4,5] Decabe-8-Carboxamide Compounds as FAAH Inhibitors | |
| WO2018049068A1 (en) | N-acyl amino acid compounds and methods of use | |
| KR20130143138A (ko) | 관절염 치료에 유용한 신규 이미다졸 유도체 | |
| US20100113465A1 (en) | 7-azaspiro[3.5]nonane-7-carboxamide compounds | |
| US11724997B2 (en) | Compounds and compositions for treating conditions associated with APJ receptor activity | |
| JP2006510728A (ja) | 糖尿病の処置に有用なアニリノピラゾール誘導体 | |
| EP4364798A2 (en) | Compounds and compositions for treating conditions associated with apj receptor activity | |
| AU2016353348A1 (en) | Heterocyclic compounds for the treatment of disease | |
| US9611232B2 (en) | Oxazolidinone and imidazolidinone compounds | |
| KR100401314B1 (ko) | 벤즈이미다졸 유도체 및 그의 약학적으로 허용되는 염 | |
| CN104245696A (zh) | 作为1型二酰基甘油o-酰基转移酶的抑制剂的化合物 | |
| JPWO1999024425A1 (ja) | ベンズイミダゾール誘導体及びその薬学的に許容される塩 | |
| JP2020506168A (ja) | 新規ＪＡＫキナーゼ阻害剤としての５−（７Ｈ−ピロロ［２，３−ｄ］ピリミジン−４−イル）−５−アザスピロ［２．５］オクタン−８−カルボン酸誘導体 | |
| KR102640385B1 (ko) | 고혈압 및/또는 폐 섬유증 치료용 조성물 | |
| HK1207632B (en) | 3,4-disubstituted oxazolidinone derivatives and their use as inhibitors of the calcium activated potassium channel | |
| WO2019179362A1 (zh) | 脒类和胍类衍生物、其制备方法及其在医药上的应用 | |
| AU2002334771A1 (en) | Spiro-hydantoin compounds useful as anti-inflammatory agents |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| FZDE | Discontinued |
Effective date: 20181025 |